Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
ELDER PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ELDER PHARMA Jun-14 |
ADCOCK INGRAM Jun-14 |
ELDER PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 380 | 319 | - | |
Low | Rs | 188 | 230 | - | |
Sales per share (Unadj.) | Rs | 489.2 | 94.9 | - | |
Earnings per share (Unadj.) | Rs | -3.2 | -23.9 | - | |
Cash flow per share (Unadj.) | Rs | 14.4 | -19.8 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 376.5 | 74.5 | - | |
Shares outstanding (eoy) | m | 20.54 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.6 | 2.9 | 20.1% | |
Avg P/E ratio | x | -89.3 | -11.5 | 777.7% | |
P/CF ratio (eoy) | x | 19.7 | -13.9 | -142.2% | |
Price / Book Value ratio | x | 0.8 | 3.7 | 20.5% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 5,832 | 46,340 | 12.6% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 2,179 | 2,908 | 74.9% | |
Avg. sales/employee | Rs Th | 0 | 3,730.7 | - | |
Avg. wages/employee | Rs Th | 0 | 677.5 | - | |
Avg. net profit/employee | Rs Th | 0 | -940.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 10,048 | 16,016 | 62.7% | |
Other income | Rs m | 257 | 112 | 228.8% | |
Total revenues | Rs m | 10,305 | 16,128 | 63.9% | |
Gross profit | Rs m | 2,921 | -2,775 | -105.2% | |
Depreciation | Rs m | 361 | 691 | 52.3% | |
Interest | Rs m | 2,756 | 434 | 635.3% | |
Profit before tax | Rs m | 60 | -3,788 | -1.6% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 125 | 237 | 52.9% | |
Profit after tax | Rs m | -65 | -4,036 | 1.6% | |
Gross profit margin | % | 29.1 | -17.3 | -167.7% | |
Effective tax rate | % | 209.1 | -6.2 | -3,346.8% | |
Net profit margin | % | -0.6 | -25.2 | 2.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 9,240 | 11,730 | 78.8% | |
Current liabilities | Rs m | 9,998 | 6,600 | 151.5% | |
Net working cap to sales | % | -7.5 | 32.0 | -23.5% | |
Current ratio | x | 0.9 | 1.8 | 52.0% | |
Inventory Days | Days | 128 | 111 | 115.7% | |
Debtors Days | Days | 602 | 124 | 485.6% | |
Net fixed assets | Rs m | 13,642 | 6,838 | 199.5% | |
Share capital | Rs m | 206 | 74 | 276.6% | |
Net worth | Rs m | 7,733 | 12,571 | 61.5% | |
Long term debt | Rs m | 4,889 | 4,418 | 110.7% | |
Total assets | Rs m | 22,882 | 23,747 | 96.4% | |
Interest coverage | x | 1.0 | -7.7 | -13.2% | |
Debt to equity ratio | x | 0.6 | 0.4 | 179.9% | |
Sales to assets ratio | x | 0.4 | 0.7 | 65.1% | |
Return on assets | % | 11.8 | -15.2 | -77.5% | |
Return on equity | % | -0.8 | -32.1 | 2.6% | |
Return on capital | % | 22.3 | -19.8 | -112.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 11,754 | 1,367 | 859.8% | |
From Investments | Rs m | -561 | -420 | 133.5% | |
From Financial Activity | Rs m | -6,762 | 4,009 | -168.7% | |
Net Cashflow | Rs m | 5,466 | 4,957 | 110.3% |
Compare ELDER PHARMA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare ELDER PHARMA With: NEULAND LABS INNOVA CAPTAB LTD. DECIPHER LABS TWILIGHT LITAKA PH. ISTREET NETWORK
Asian markets traded lower on Friday tracking overnight losses on Wall Street and inflation data from Japan.